Multivariable analysis of outcomes for recipients of UDLI for relapsed disease
| Predictor . | Survival6-150 . | Disease-free Survival6-150 . | ||
|---|---|---|---|---|
| P Value . | Hazard Ratio . | P Value . | Hazard Ratio . | |
| BMT to UDLI more than 1 year | ns | .0026-151 | 0.09 | |
| BMT to relapse more than 1 year | .00156-150 | 0.28 | ns | |
| Acute GVHD at BMT | ns | ns | ||
| T-cell–depleted graft | ns | ns | ||
| Predictor . | Survival6-150 . | Disease-free Survival6-150 . | ||
|---|---|---|---|---|
| P Value . | Hazard Ratio . | P Value . | Hazard Ratio . | |
| BMT to UDLI more than 1 year | ns | .0026-151 | 0.09 | |
| BMT to relapse more than 1 year | .00156-150 | 0.28 | ns | |
| Acute GVHD at BMT | ns | ns | ||
| T-cell–depleted graft | ns | ns | ||
ns indicates not significant.
Proportion hazards regression model.
When adjusted for a diagnosis of AML, the time interval from BMT to relapse of more than 1 year remains a significant predictor of survival (P = .0033).
When adjusted for a diagnosis of AML, the time interval from BMT to UDLI of more than 1 year remains a significant predictor of disease-free survival (P = .003).